Yohei Doi

List of Publications by Year
in descending order

Source: //exaly.com/author-pdf/6998654/publications.pdf

Version: 2024-02-01

381	25,272	8910 75	9570 144
papers	citations	h-index	g-index

399	399	399	25850
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Findings from a discontinued clinical trial of favipiravir in high-risk patients with early-onset COVID-19. Journal of Infection and Chemotherapy, 2024, 30, 219-227.	1.7	1
2	Structural insights into the molecular mechanism of high-level ceftazidimeâ€“avibactam resistance conferred by CMY-185. MBio, 2024, 15, .	4.4	1
3	In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitals. Antimicrobial Agents and Chemotherapy, 2024, 68, .	3.4	3
4	Differential in vitro susceptibility to ampicillin/ceftriaxone combination therapy among Enterococcus faecalis infective endocarditis clinical isolates. Journal of Antimicrobial Chemotherapy, 2024, 79, 801-809.	3.2	0
5	Levofloxacin-induced MexS mutation triggers imipenem-relebactam resistance in a KPC-producing Pseudomonas aeruginosa. International Journal of Antimicrobial Agents, 2024, 63, 107119.	3.3	0
6	How Much More Efficient Are Adaptive Platform Trials Than Multiple Standâ€Alone Trials? A Comprehensive Simulation Study for Streamlining Drug Development During a Pandemic. Clinical Pharmacology and Therapeutics, 2024, 115, 1372-1382.	4.9	0
7	Clinical and genomic characteristics of IMP-producing Enterobacter cloacae complex and Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2024, 68, .	3.4	1
8	Frequency of cefiderocol heteroresistance among patients treated with cefiderocol for carbapenem-resistant Acinetobacter baumannii infections. JAC-Antimicrobial Resistance, 2024, 6, .	2.1	0
9	Short-course remdesivir for healthcare-associated COVID-19: Case series from a non-acute care hospital. Journal of Infection and Chemotherapy, 2023, 29, 95-97.	1.7	4
10	An early return-to-work program for COVID-19 close contacts in healthcare during the Omicron wave in Japan. Journal of Infection and Chemotherapy, 2023, 29, 102-104.	1.7	1
11	Favipiravir for symptomatic COVID-19: A nationwide observational cohort study. Journal of Infection and Chemotherapy, 2023, 29, 150-156.	1.7	9
12	Early initiation of three-drug combinations for the treatment of carbapenem-resistant A. baumannii among COVID-19 patients. Journal of Antimicrobial Chemotherapy, 2023, 78, 1034-1040.	3.2	7
13	Comparison of Biological Activities of BafA Family Autotransporters within Bartonella Species Derived from Cats and Rodents. Infection and Immunity, 2023, 91, .	2.4	1
14	Genomic Epidemiology of Carbapenem-Resistant Klebsiella in Qatar: Emergence and Dissemination of Hypervirulent Klebsiella pneumoniae Sequence Type 383 Strains. Antimicrobial Agents and Chemotherapy, 2023, 67, .	3.4	9
15	Carbonic Anhydrase Inhibition as a Target for Antibiotic Synergy in Enterococci. Microbiology Spectrum, 2023, 11, .	3.0	9
16	High-level ceftazidime/avibactam resistance inEscherichia coliconferred by the novel plasmid-mediated Î²-lactamase CMY-185 variant. Journal of Antimicrobial Chemotherapy, 2023, 78, 2442-2450.	3.2	6
17	Genomic epidemiology and antibiotic susceptibility profiling of uropathogenic Escherichia coli among children in the United States. MSphere, 2023, 8, .	3.1	2
18	Daily fosfomycin versus levofloxacin for complicated urinary tract infections. MBio, 2023, 14, .	4.4	1

#	Article	IF	Citations
19	In vitro activity of cefiderocol against Pseudomonas aeruginosa demonstrating evolved resistance to novel Î²-lactam/Î²-lactamase inhibitors. JAC-Antimicrobial Resistance, 2023, 5, .	2.1	5
20	Priorities and Progress in Gram-negative Bacterial Infection Research by the Antibacterial Resistance Leadership Group. Clinical Infectious Diseases, 2023, 77, S305-S313.	5.7	2
21	A Phase I/II Clinical Trial of Intradermal, Controllable Self-Replicating Ribonucleic Acid Vaccine EXG-5003 against SARS-CoV-2. Vaccines, 2023, 11, 1767.	4.5	1
22	Utility and Applicability of Rapid Diagnostic Testing in Antimicrobial Stewardship in the Asia-Pacific Region: A Delphi Consensus. Clinical Infectious Diseases, 2022, 74, 2067-2076.	5.7	14
23	Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study. Lancet Infectious Diseases, The, 2022, 22, 401-412.	8.9	152
24	Fetal and maternal inflammatory response in the setting of maternal intrapartum fever with and without clinical and histologic chorioamnionitis. American Journal of Obstetrics & Gynecology MFM, 2022, 4, 100539.	2.5	7
25	Baseline uric acid levels and steady-state favipiravir concentrations are associated with occurrence of hyperuricemia among COVID-19 patients. International Journal of Infectious Diseases, 2022, 115, 218-223.	3.3	7
26	Survey of infectious diseases providers reveals variability in duration of antibiotic therapy for the treatment of Gram-negative bloodstream infections. JAC-Antimicrobial Resistance, 2022, 4, dlac005.	2.1	4
27	A Novel Lipid-Based MALDI-TOF Assay for the Rapid Detection of Colistin-Resistant Enterobacter Species. Microbiology Spectrum, 2022, 10, e0144521.	3.0	13
28	Pharmacokinetic/Pharmacodynamic Analysis and Dose Optimization of Cefmetazole and Flomoxef against Extended-Spectrum Î²-Lactamase-Producing Enterobacterales in Patients with Invasive Urinary Tract Infection Considering Renal Function. Antibiotics, 2022, 11, 456.	3.8	3
29	Effectiveness of Favipiravir on Nonsevere, Early-Stage COVID-19 in Japan: A Large Observational Study Using the COVID-19 Registry Japan. Infectious Diseases and Therapy, 2022, 11, 1075-1087.	4.1	8
30	Isolation and Characterization of Lytic Bacteriophages Targeting Diverse Enterobacter spp. Clinical Isolates. Phage, 2022, 3, 50-58.	2.3	1
31	Carbapenem-Resistant Acinetobacter baumannii in U.S. Hospitals: Diversification of Circulating Lineages and Antimicrobial Resistance. MBio, 2022, 13, e0275921.	4.4	37
32	Dissecting the clonality of I1 plasmids using ORF-based binarized structure network analysis of plasmids (OSNAp). Journal of Infection and Chemotherapy, 2022, 28, 473-479.	1.7	1
33	The Passenger Domain of Bartonella bacilliformis BafA Promotes Endothelial Cell Angiogenesis via the VEGF Receptor Signaling Pathway. MSphere, 2022, 7, e0008122.	3.1	4
34	Newly developed artificial intelligence algorithm for COVID-19 pneumonia: utility of quantitative CT texture analysis for prediction of favipiravir treatment effect. Japanese Journal of Radiology, 2022, 40, 800-813.	2.5	13
35	Contemporary Clinical and Molecular Epidemiology of Vancomycin-Resistant Enterococcal Bacteremia: A Prospective Multicenter Cohort Study (VENOUS I). Open Forum Infectious Diseases, 2022, 9, ofab616.	0.9	26
36	MCR-1-dependent lipid remodelling compromises the viability of Gram-negative bacteria. Emerging Microbes and Infections, 2022, 11, 1236-1249.	6.6	16

#	Article	IF	Citations
37	Prediction of Antibiotic Resistance Evolution by Growth Measurement of All Proximal Mutants of Beta-Lactamase. Molecular Biology and Evolution, 2022, 39, .	9.2	6
38	Treatment of carbapenem-resistantPseudomonas aeruginosainfections: a case for cefiderocol. Expert Review of Anti-Infective Therapy, 2022, 20, 1077-1094.	4.5	22
39	Rational Framework for the Design of Trp- and Arg-Rich Peptide Antibiotics Against Multidrug-Resistant Bacteria. Frontiers in Microbiology, 2022, 13, .	3.6	5
40	A Systems-Based Analysis of Mono- and Combination Therapy for Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections. Antimicrobial Agents and Chemotherapy, 2022, 66, .	3.4	4
41	Periprosthetic joint infection due to Mycoplasma hominis in a multiple sclerosis patient treated with fingolimod. Journal of Infection and Chemotherapy, 2022, 28, 1672-1676.	1.7	4
42	Clinical Impact of Ceftriaxone Resistance in Escherichia coli Bloodstream Infections: A Multicenter Prospective Cohort Study. Open Forum Infectious Diseases, 2022, 9, .	0.9	7
43	Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infectious Diseases, The, 2021, 21, 226-240.	8.9	484
44	The evolution of polymer conjugation and drug targeting for the delivery of proteins and bioactive molecules. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2021, 13, e1689.	6.8	11
45	Insights on Coronavirus Disease 2019 Epidemiology From a Historic Cruise Ship Quarantine. Clinical Infectious Diseases, 2021, 72, e458-e459.	5.7	3
46	Antibacterial Resistance Leadership Group 2.0: Back to Business. Clinical Infectious Diseases, 2021, 73, 730-739.	5.7	7
47	Molecular characterization of clinical carbapenem-resistant Enterobacterales from Qatar. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 1779-1785.	3.1	24
48	Ampicillin-Ceftriaxone vs Ampicillin-Gentamicin for Definitive Therapy of Enterococcus faecalis Infective Endocarditis: A Propensity Scoreâ€“Matched, Retrospective Cohort Analysis. Open Forum Infectious Diseases, 2021, 8, ofab102.	0.9	14
49	Outcomes of Adjunctive Therapy with Intravenous Cefoperazone-Sulbactam for Ventilator-Associated Pneumonia Due to Carbapenem-Resistant Acinetobacter baumannii. Infection and Drug Resistance, 2021, Volume 14, 1255-1264.	2.8	4
50	Elastase Activity From Pseudomonas aeruginosa Respiratory Isolates and ICU Mortality. Chest, 2021, 160, 1624-1633.	0.9	17
51	Diagnostic accuracy of LAMP versus PCR over the course of SARS-CoV-2 infection. International Journal of Infectious Diseases, 2021, 107, 195-200.	3.3	59
52	Characterization of KPC-82, a KPC-2 Variant Conferring Resistance to Ceftazidime-Avibactam in a Carbapenem-Nonsusceptible Clinical Isolate of Citrobacter koseri. Antimicrobial Agents and Chemotherapy, 2021, 65, e0015021.	3.4	13
53	Rapid diagnostic testing for antimicrobial stewardship: Utility in Asia Pacific. Infection Control and Hospital Epidemiology, 2021, 42, 864-868.	2.0	9
54	PhaseÂII Clinical Trial of Combination Therapy with Favipiravir and Methylprednisolone for COVID-19 with Non-Critical Respiratory Failure. Infectious Diseases and Therapy, 2021, 10, 2353-2369.	4.1	5

#	Article	IF	Citations
55	Virological and genomic analysis of SARS-CoV-2 from a favipiravir clinical trial cohort. Journal of Infection and Chemotherapy, 2021, 27, 1350-1356.	1.7	2
56	Functional and Structural Characterization of Acquired 16S rRNA Methyltransferase NpmB1 Conferring Pan-Aminoglycoside Resistance. Antimicrobial Agents and Chemotherapy, 2021, 65, e0100921.	3.4	13
57	Duration of carbapenemase-producing Enterobacteriales carriage among ICU patients in Miami, FL: A retrospective cohort study. American Journal of Infection Control, 2021, 49, 1281-1286.	2.5	4
58	Retrospective evaluation of appropriate dosing of cefmetazole for invasive urinary tract infection due to extended-spectrum Î²-lactamase-producing Escherichia coli. Journal of Infection and Chemotherapy, 2021, 27, 1602-1606.	1.7	10
59	Extensively drug-resistant IMP-16-producing Pseudomonas monteilii isolated from cerebrospinal fluid. Infection, Genetics and Evolution, 2021, 87, 104658.	2.3	1
60	Variability in oral antibiotic step-down therapy in the management of Gram-negative bloodstream infections. International Journal of Antimicrobial Agents, 2021, 58, 106451.	3.3	11
61	Delayed Injection Site Reaction After mRNA-1273 Vaccination in Japan: A Retrospective, Cross-Sectional Study. Open Forum Infectious Diseases, 2021, 8, ofab497.	0.9	6
62	Risk factors for the development of infections associated with carbapenemase-producing Enterobacteriaceae among previously colonized patients: A retrospective cohort study. Infection Control and Hospital Epidemiology, 2021, 42, 1-4.	2.0	0
63	Comparison of sCIM and Other Phenotypic Detection Methods for Carbapenemase-Producing Enterobacterales. Microbiology Spectrum, 2021, 9, e0160821.	3.0	3
64	Development of Knowledge-Based Engineering System for Structural Size Optimization of External Fixation Device. Applied Sciences (Switzerland), 2021, 11, 10775.	2.6	3
65	In Vitro Evolution of Cefiderocol Resistance in an NDM-Producing Klebsiella pneumoniae Due to Functional Loss of CirA. Microbiology Spectrum, 2021, 9, e0177921.	3.0	34
66	Transmission of NDM-5-Producing and OXA-48-Producing Escherichia coli Sequence Type 648 by International Visitors without Previous Medical Exposure. Microbiology Spectrum, 2021, 9, e0182721.	3.0	7
67	The Pitt Bacteremia Score Predicts Mortality in Nonbacteremic Infections. Clinical Infectious Diseases, 2020, 70, 1826-1833.	5.7	63
68	Effect of withholding feeds on transfusion-related acute gut injury in preterm infants: a pilot randomized controlled trial. Journal of Maternal-Fetal and Neonatal Medicine, 2020, 33, 4139-4144.	1.7	6
69	Polymyxin Resistance in Klebsiella pneumoniae: Complexity at Every Level. Clinical Infectious Diseases, 2020, 70, 2092-2094.	5.7	7
70	ORF-based binarized structure network analysis of plasmids (OSNAp), a novel approach to core gene-independent plasmid phylogeny. Plasmid, 2020, 108, 102477.	1.4	11
71	Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae Infections. Clinical Infectious Diseases, 2020, 71, 667-671.	5.7	74
72	Aminoglycoside Resistance. Infectious Disease Clinics of North America, 2020, 34, 887-902.	4.2	40

#	Article	IF	Citations
73	The Bartonella autotransporter BafA activates the host VEGF pathway to drive angiogenesis. Nature Communications, 2020, 11, 3571.	13.2	22
74	Genomic patterns and characterizations of chromosomally-encoded mcr-1 in Escherichia coli populations. Gut Pathogens, 2020, 12, 55.	3.9	10
75	In Vivo Evolution of CTX-M-215, a Novel Narrow-Spectrum Î²-Lactamase in an Escherichia coli Clinical Isolate Conferring Resistance to Mecillinam. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.4	4
76	A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.4	183
77	Pathogenicity of mcr-1-positive Escherichia coli from human infections. Lancet Microbe, The, 2020, 1, e195.	6.7	0
78	Increased Alternative Complement Pathway Function Improves Survival During Critical Illness. , 2020, , .		0
79	Pseudomonas Aeruginosa Protease and Elastase Activity Are Associated with Increased 30-Day Mortality in ICU Patients. , 2020, , .		0
80	Structural Basis of Reduced Susceptibility to Ceftazidime-Avibactam and Cefiderocol in Enterobacter cloacae Due to AmpC R2 Loop Deletion. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.4	57
81	Enhanced therapeutic index of an antimicrobial peptide in mice by increasing safety and activity against multidrug-resistant bacteria. Science Advances, 2020, 6, eaay6817.	10.9	87
82	Dynamics of mcr-1 prevalence and mcr-1-positive Escherichia coli after the cessation of colistin use as a feed additive for animals in China: a prospective cross-sectional and whole genome sequencing-based molecular epidemiological study. Lancet Microbe, The, 2020, 1, e34-e43.	6.7	88
83	Natural History of Asymptomatic SARS-CoV-2 Infection. New England Journal of Medicine, 2020, 383, 885-886.	30.1	253
84	Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study. Lancet Infectious Diseases, The, 2020, 20, 731-741.	8.9	200
85	Clinical and Genomic Epidemiology of Carbapenem-Nonsusceptible Citrobacter spp. at a Tertiary Health Care Center over 2 Decades. Journal of Clinical Microbiology, 2020, 58, .	4.4	24
86	TNF-Î± and INF-Î³ primed canine stem cell-derived extracellular vesicles alleviate experimental murine colitis. Scientific Reports, 2020, 10, 2115.	3.4	47
87	OXA-23 and OXA-40 producing carbapenem-resistant Acinetobacter baumannii in Central Illinois. Diagnostic Microbiology and Infectious Disease, 2020, 97, 114999.	1.8	9
88	Clinical Evolution of AmpC-Mediated Ceftazidime-Avibactam and Cefiderocol Resistance in Enterobacter cloacae Complex Following Exposure to Cefepime. Clinical Infectious Diseases, 2020, 71, 2713-2716.	5.7	61
89	Colistin and its role in the Era of antibiotic resistance: an extended review (2000â€“2019). Emerging Microbes and Infections, 2020, 9, 868-885.	6.6	402
90	Epidemiology of carbapenem-resistant Enterobacteriaceae in hospitals of a large healthcare system in Miami, Florida from 2012 to 2016: Five years of experience with an internal registry. American Journal of Infection Control, 2020, 48, 1341-1347.	2.5	4

#	Article	IF	Citations
91	Molecular Epidemiology of Ceftriaxone-Nonsusceptible Enterobacterales Isolates in an Academic Medical Center in the United States. Open Forum Infectious Diseases, 2019, 6, ofz353.	0.9	44
92	Fosfomycin for treatment of multidrug-resistant pathogens causing urinary tract infection: A real-world perspective and review of the literature. Diagnostic Microbiology and Infectious Disease, 2019, 95, 114856.	1.8	26
93	Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections. Clinical Infectious Diseases, 2019, 69, S565-S575.	5.7	393
94	Study of melting transition on biphenyl by Raman scattering. AIP Advances, 2019, 9, 095049.	1.3	1
95	High-Level Carbapenem Resistance in OXA-232-Producing Raoultella ornithinolytica Triggered by Ertapenem Therapy. Antimicrobial Agents and Chemotherapy, 2019, 64, .	3.4	12
96	Antimicrobial treatment challenges in the era of carbapenem resistance. Diagnostic Microbiology and Infectious Disease, 2019, 94, 413-425.	1.8	51
97	Reduced ceftazidime and ertapenem susceptibility due to production of OXA-2 in Klebsiella pneumoniae ST258. Journal of Antimicrobial Chemotherapy, 2019, 74, 2203-2208.	3.2	5
98	Plasmid Carrying bla CTX-M-2 and bla GES-1 in Extensively Drug-Resistant Pseudomonas aeruginosa from Cerebrospinal Fluid. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.4	5
99	Use of a cohorting-unit and systematic surveillance cultures to control a Klebsiella pneumoniae carbapenemase (KPC)â€“producing Enterobacteriaceae outbreak. Infection Control and Hospital Epidemiology, 2019, 40, 767-773.	2.0	5
100	Left ventricular assist device-associated endocarditis involving multiple clones of Staphylococcus aureus with distinct antimicrobial susceptibility patterns. International Journal of Infectious Diseases, 2019, 84, 44-47.	3.3	5
101	Adjunctive therapy of intravenous colistin to intravenous tigecycline for adult patients with non-bacteremic post-surgical intra-abdominal infection due to carbapenem-resistant Acinetobacter baumannii. Journal of Infection and Chemotherapy, 2019, 25, 681-686.	1.7	12
102	Use of online tools for antimicrobial resistance prediction by whole-genome sequencing in methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). Journal of Global Antimicrobial Resistance, 2019, 19, 136-143.	2.5	19
103	Clinical characteristics and outcomes of community and hospital-acquired Acinetobacter baumannii bacteremia. Journal of Microbiology, Immunology and Infection, 2019, 52, 796-806.	3.1	35
104	A Multiport Solar-assisted SRM Drive for HEV Applications. , 2019, , .		5
105	A Primer on AmpC Î²-Lactamases: Necessary Knowledge for an Increasingly Multidrug-resistant World. Clinical Infectious Diseases, 2019, 69, 1446-1455.	5.7	171
106	508. Gentamicin Non-susceptibility is Associated with Persistence of Carbapenem-Resistant Klebsiella pneumoniae in the Urinary Tract. Open Forum Infectious Diseases, 2019, 6, S246-S246.	0.9	0
107	622. The Accessory Genome in Enterococcal Bacteremia: Results from the Vancomycin-Resistant Enterococcal Bacteremia Outcomes Study (VENOUS). Open Forum Infectious Diseases, 2019, 6, S289-S289.	0.9	0
108	The Elucidation of Pathogenicity of Carbapenemase-Producing Klebsiella Pneumoniae Pulmonary Infection Using Single Cell RNAseq. , 2019, , .		0

#	Article	IF	Citations
109	630. Clinical and Molecular Characteristics of Carbapenem-Resistant Enterobacteriaceae in Qatar: A Retrospective and Prospective Observational Study. Open Forum Infectious Diseases, 2019, 6, S292-S292.	0.9	0
110	485. Clinical and Molecular Epidemiology of Carbapenem Non-susceptible Citrobacter sp.. Open Forum Infectious Diseases, 2019, 6, S237-S238.	0.9	1
111	2282. Empiric Antimicrobial Therapy and Clinical Outcomes of Infections due to ESBL-producing Klebsiella pneumoniae. Open Forum Infectious Diseases, 2019, 6, S781-S782.	0.9	0
112	605. Identification of a Novel CMY-Variant Enzyme in a Clinical Escherichia coli Strain with Treatment-Emergent Ceftazidimeâ€“Avibactam Resistance. Open Forum Infectious Diseases, 2019, 6, S283-S283.	0.9	0
113	636. Genome Epidemiology of Carbapenem-Resistant Acinetobacter baumannii (CRAb) in the United States. Open Forum Infectious Diseases, 2019, 6, S295-S295.	0.9	2
114	Pseudomonas Aeruginosa Protease and Elastase Activity Are Common in ICU Respiratory Isolates. , 2019, , .		0
115	Designing A Pathogen-Focused Study To Address The High Unmet Medical Need Represented By Carbapenem-Resistant Gram-Negative Pathogens â€“ The International, Multicenter, Randomized, Open-Label, Phase 3 CREDIBLE-CR Study . Infection and Drug Resistance, 2019, Volume 12, 3607-3623.	2.8	26
116	Caching Optimization for D2D-Assisted Heterogeneous Wireless Networks. , 2019, , .		4
117	Rapid Microbial Identification and Antibiotic Resistance Detection by Mass Spectrometric Analysis of Membrane Lipids. Analytical Chemistry, 2019, 91, 1286-1294.	6.8	41
118	A Prospective Study of Acinetobacter baumannii Complex Isolates and Colistin Susceptibility Monitoring by Mass Spectrometry of Microbial Membrane Glycolipids. Journal of Clinical Microbiology, 2019, 57, .	4.4	22
119	The Role of Trimethoprim/Sulfamethoxazole in the Treatment of Infections Caused by Carbapenem-Resistant Enterobacteriaceae. Open Forum Infectious Diseases, 2019, 6, ofy351.	0.9	12
120	Effects of KPC Variant and Porin Genotype on the In Vitro Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.4	62
121	Small-Molecule Inhibitor of FosA Expands Fosfomycin Activity to Multidrug-Resistant Gram-Negative Pathogens. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.4	11
122	Evaluation of the Accelerate Pheno System for Identification of Acinetobacter Clinical Isolates and Minocycline Susceptibility Testing. Journal of Clinical Microbiology, 2019, 57, .	4.4	3
123	New Treatment Options against Carbapenem-Resistant Acinetobacter baumannii Infections. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.4	219
124	Emergence of CMY-2-Producing Salmonella Heidelberg Associated with IncI1 Plasmids Isolated from Poultry in Brazil. Microbial Drug Resistance, 2019, 25, 271-276.	2.0	15
125	Clostridioides difficile: a potential source of NpmA in the clinical environment. Journal of Antimicrobial Chemotherapy, 2019, 74, 521-523.	3.2	13
126	Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae. Clinical Infectious Diseases, 2018, 66, 163-171.	5.7	514

#	Article	IF	Citations
127	Origin of the plasmid-mediated fosfomycin resistance gene fosA3. Journal of Antimicrobial Chemotherapy, 2018, 73, 373-376.	3.2	27
128	High Rates of Human Fecal Carriage of mcr-1â€“Positive Multidrug-Resistant Enterobacteriaceae Emerge in China in Association With Successful Plasmid Families. Clinical Infectious Diseases, 2018, 66, 676-685.	5.7	70
129	Susceptibility of colistin-resistant pathogens to predatory bacteria. Research in Microbiology, 2018, 169, 52-55.	2.2	36
130	Frequency and Mechanisms of Spontaneous Fosfomycin Nonsusceptibility Observed upon Disk Diffusion Testing of Escherichia coli. Journal of Clinical Microbiology, 2018, 56, .	4.4	34
131	Outcomes of adjunctive therapy with intrathecal or intraventricular administration of colistin for post-neurosurgical meningitis and ventriculitis due to carbapenem-resistant acinetobacter baumannii. International Journal of Antimicrobial Agents, 2018, 51, 646-650.	3.3	27
132	1180. Addition of Chronic Kidney Disease Status to Pitt Bacteremia Score Improves Prediction of Mortality in Patients With Carbapenem-Resistant Enterobacteriaceae Infections. Open Forum Infectious Diseases, 2018, 5, S356-S357.	0.9	0
133	2065. Whole Genome Sequencing for Antimicrobial Resistance Prediction in MRSA and VRE: A Real-world Application. Open Forum Infectious Diseases, 2018, 5, S603-S603.	0.9	0
134	Draft Genome Sequences of bla KPC -Containing Enterobacter aerogenes, Citrobacter freundii, and Citrobacter koseri Strains. Genome Announcements, 2018, 6, .	0.8	2
135	Detection of high-risk carbapenem-resistant Klebsiella pneumoniae and Enterobacter cloacae isolates using volatile molecular profiles. Scientific Reports, 2018, 8, 13297.	3.4	28
136	Pseudomonas aeruginosa utilizes host polyunsaturated phosphatidylethanolamines to trigger theft-ferroptosis in bronchial epithelium. Journal of Clinical Investigation, 2018, 128, 4639-4653.	8.2	178
137	Procalcitonin-Guided Use of Antibiotics for Lower Respiratory Tract Infection. New England Journal of Medicine, 2018, 379, 236-249.	30.1	319
138	Comparison of three cut-offs to diagnose clinically significant portal hypertension by liver stiffness in chronic viral liver diseases: a meta-analysis. European Radiology, 2018, 28, 5221-5230.	4.6	20
139	Absence of fosfomycin resistance in gastrointestinal Escherichia coli following fosfomycin therapy. Journal of Global Antimicrobial Resistance, 2018, 14, 109-110.	2.5	0
140	Respiratory Microbiome Profiling for Etiologic Diagnosis of Pneumonia in Mechanically Ventilated Patients. Frontiers in Microbiology, 2018, 9, 1413.	3.6	63
141	Novel Polymyxin Combination With Antineoplastic Mitotane Improved the Bacterial Killing Against Polymyxin-Resistant Multidrug-Resistant Gram-Negative Pathogens. Frontiers in Microbiology, 2018, 9, 721.	3.6	37
142	Diversity among blaKPC-containing plasmids in Escherichia coli and other bacterial species isolated from the same patients. Scientific Reports, 2018, 8, 10291.	3.4	34
143	Proposal for assignment of allele numbers for mobile colistin resistance (mcr) genes. Journal of Antimicrobial Chemotherapy, 2018, 73, 2625-2630.	3.2	104
144	Diversity of High-Level Aminoglycoside Resistance Mechanisms among Gram-Negative Nosocomial Pathogens in Brazil. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.4	11

#	Article	IF	Citations
145	Phylogenomics of colistin-susceptible and resistant XDR Acinetobacter baumannii. Journal of Antimicrobial Chemotherapy, 2018, 73, 2952-2959.	3.2	42
146	Evolution of Sequence Type 4821 Clonal Complex Meningococcal Strains in China from Prequinolone to Quinolone Era, 1972â€“2013. Emerging Infectious Diseases, 2018, 24, 683-690.	4.4	11
147	Colistin Resistance in Carbapenem-Resistant Klebsiella pneumoniae: Laboratory Detection and Impact on Mortality. Clinical Infectious Diseases, 2017, 64, ciw805.	5.7	153
148	Carriage of Î²-lactamase-producing Enterobacteriaceae by Chinese travellers. Lancet Infectious Diseases, The, 2017, 17, 138-139.	8.9	7
149	Prevalence, risk factors, outcomes, and molecular epidemiology of mcr-1 -positive Enterobacteriaceae in patients and healthy adults from China: an epidemiological and clinical study. Lancet Infectious Diseases, The, 2017, 17, 390-399.	8.9	311
150	Carbapenem-Resistant Enterobacteriaceae. Clinics in Laboratory Medicine, 2017, 37, 303-315.	1.5	171
151	Disposable Bronchoscope Model for Simulating Endoscopic Reprocessing and Surveillance Cultures. Infection Control and Hospital Epidemiology, 2017, 38, 136-142.	2.0	6
152	Effects of Quantum Spin-1/2Impurities on the Magnetic Properties of Zigzag Spin Chains. Physical Review Letters, 2017, 118, 107201.	8.0	8
153	Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infectious Diseases, The, 2017, 17, 726-734.	8.9	379
154	IncX2 and IncX1-X2 Hybrid Plasmids Coexisting in a FosA6-Producing Escherichia coli Strain. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.4	14
155	The ecology of extended-spectrum Î²-lactamases (ESBLs) in the developed world. Journal of Travel Medicine, 2017, 24, S44-S51.	3.0	189
156	Gram-Negative Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group. Clinical Infectious Diseases, 2017, 64, S30-S35.	5.7	117
157	MCR-1-producing Klebsiella pneumoniae outbreak in China. Lancet Infectious Diseases, The, 2017, 17, 577.	8.9	48
158	Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.4	373
159	Structural Modification of Lipopolysaccharide Conferred by mcr-1 in Gram-Negative ESKAPE Pathogens. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.4	98
160	Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance. Clinical Infectious Diseases, 2017, 65, 110-120.	5.7	234
161	Effective Antibiotic Conservation by Emergency Antimicrobial Stewardship During a Drug Shortage. Infection Control and Hospital Epidemiology, 2017, 38, 356-359.	2.0	15
162	Inhibition of Fosfomycin Resistance Protein FosA by Phosphonoformate (Foscarnet) in Multidrug-Resistant Gram-Negative Pathogens. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.4	19

#	Article	IF	Citations
163	Structural modification of LPS in colistin-resistant, KPC-producing Klebsiella pneumoniae. Journal of Antimicrobial Chemotherapy, 2017, 72, 3035-3042.	3.2	63
164	Small molecule adjuvants that suppress both chromosomal and mcr-1 encoded colistin-resistance and amplify colistin efficacy in polymyxin-susceptible bacteria. Bioorganic and Medicinal Chemistry, 2017, 25, 5749-5753.	3.1	22
165	Structure and Dynamics of FosA-Mediated Fosfomycin Resistance in Klebsiella pneumoniae and Escherichia coli. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.4	28
166	Widespread Fosfomycin Resistance in Gram-Negative Bacteria Attributable to the Chromosomal fosA Gene. MBio, 2017, 8, .	4.4	146
167	Emergence of mcr-1 in Raoultella ornithinolytica and Escherichia coli Isolates from Retail Vegetables in China. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.4	68
168	Identification of the ESKAPE pathogens by mass spectrometric analysis of microbial membrane glycolipids. Scientific Reports, 2017, 7, 6403.	3.4	68
169	Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study. International Journal of Antimicrobial Agents, 2017, 50, 664-672.	3.3	8
170	CXC Chemokines Exhibit Bactericidal Activity against Multidrug-Resistant Gram-Negative Pathogens. MBio, 2017, 8, .	4.4	12
171	Proposed primary endpoints for use in clinical trials that compare treatment options for bloodstream infection in adults: a consensus definition. Clinical Microbiology and Infection, 2017, 23, 533-541.	6.5	62
172	Coproduction of MCR-1 and NDM-1 by Colistin-Resistant Escherichia coli Isolated from a Healthy Individual. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.4	36
173	Prevalence of Extended-Spectrum Î²-Lactamases CTX-M-8 and CTX-M-2-Producing Salmonella Serotypes from Clinical and Nonhuman Isolates in Brazil. Microbial Drug Resistance, 2017, 23, 580-589.	2.0	19
174	The global epidemiology of carbapenemase-producing Enterobacteriaceae. Virulence, 2017, 8, 460-469.	4.5	654
175	Molecular epidemiology and spatiotemporal analysis of hospital-acquired Acinetobacter baumannii infection in a tertiary care hospital in southern Thailand. Journal of Hospital Infection, 2017, 95, 53-58.	3.1	10
176	Elimination of Antibiotic Resistant Surgical Implant Biofilms Using an Engineered Cationic Amphipathic Peptide WLBU2. Scientific Reports, 2017, 7, 18098.	3.4	37
177	Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum Î²-Lactamaseâ€“Producing Enterobacteriaceae: Results From the INCREMENT Cohort. Clinical Infectious Diseases, 2017, 65, 1615-1623.	5.7	45
178	A Prospective Observational Study of the Epidemiology, Management, and Outcomes of Skin and Soft Tissue Infections Due to Carbapenem-Resistant Enterobacteriaceae. Open Forum Infectious Diseases, 2017, 4, ofx157.	0.9	22
179	Ceftazidimeâ€“avibactam Susceptibility Patterns in Carbapenem-Resistant Enterobacteriaceae in the USA: Results from the Consortium on Resistance against Carbapenems in Klebsiella and Other Enterobacteriaceae (CRACKLE-2). Open Forum Infectious Diseases, 2017, 4, S133-S134.	0.9	2
180	Carbapenem-Resistant Enterobacteriaceae Infections in Patients on Renal Replacement Therapy. Open Forum Infectious Diseases, 2017, 4, ofx216.	0.9	6

#	Article	IF	Citations
181	High-Level Fosfomycin Resistance in Vancomycin-Resistant Enterococcus faecium. Emerging Infectious Diseases, 2017, 23, 1902-1904.	4.4	24
182	mcr-1â^'Harboring Salmonella enterica Serovar Typhimurium Sequence Type 34 in Pigs, China. Emerging Infectious Diseases, 2017, 23, 291-295.	4.4	63
183	Design and rationale of the Procalcitonin Antibiotic Consensus Trial (ProACT), a multicenter randomized trial of procalcitonin antibiotic guidance in lower respiratory tract infection. BMC Emergency Medicine, 2017, 17, 25.	2.0	10
184	Contribution of the TetB Efflux Pump to Minocycline Susceptibility among Carbapenem-Resistant Acinetobacter baumannii Strains. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.4	20
185	Coexistence of Hypertension and Diabetes Mellitus in Elderly Population of Arar City, Northern Saudi Arabia. The Egyptian Journal of Hospital Medicine, 2017, 69, 3154-3159.	0.1	1
186	The association of IL-17A polymorphisms with IL-17A serum levels and risk of ischemic stroke. Oncotarget, 2017, 8, 103499-103508.	2.1	19
187	Salim Tamari and Issam Nassar , eds. The Storyteller of Jerusalem: The Life and Times of Wasif Jawhariyyeh, 1904â€"1948. Translated by Nada Elzeer , foreword by Rachel Beckles Willson . Northampton, MA: Olive Tree Press, 2014. 304 pages. Paper US$25.00 ISBN 978-1566569255.. Review of Middle East Studies, 2016, 50, 128-132.	0.0	0
188	In Vitro Global Surveillance of Eravacycline and Comparators Against Staphylococcus spp. and Enterococcus spp. Over a 3-Year Period (2013â€"2015). Open Forum Infectious Diseases, 2016, 3, .	0.9	3
189	Possible Transmission ofmcr-1â€"HarboringEscherichia colibetween Companion Animals and Human. Emerging Infectious Diseases, 2016, 22, 1679-1681.	4.4	126
190	New Delhi Metallo-Î²-Lactamase-1â€"ProducingKlebsiella pneumoniae, Florida, USA1. Emerging Infectious Diseases, 2016, 22, 744-746.	4.4	15
191	Epidemiology and Management of Skin and Soft Tissue Infection (SSTI) Due to Carbapenem-Resistant Enterobacteriaceae: A Report From The Consortium on Resistance against Carbapenems in Klebsiella pneumoniae (CRaCKle). Open Forum Infectious Diseases, 2016, 3, .	0.9	0
192	In Vitro Global Surveillance of Eravacycline and Comparators Against Enterobacteriaceae, Acinetobacter baumannii, Stenotrophomonas maltophilia, Including Multidrug-Resistant (MDR) Isolates, Over a 3-Year Period (2013â€"2015). Open Forum Infectious Diseases, 2016, 3, .	0.9	6
193	Aliphatic Halogenase Enables Lateâ€Stage Câ^'H Functionalization: Selective Synthesis of a Brominated Fischerindole Alkaloid with Enhanced Antibacterial Activity. ChemBioChem, 2016, 17, 466-470.	2.8	26
194	Hospital Readmissions in Patients With Carbapenem-ResistantKlebsiella pneumoniae. Infection Control and Hospital Epidemiology, 2016, 37, 281-288.	2.0	24
195	Comparative Genome Analysis of Extended-Spectrum-Î²-Lactamase-Producing Escherichia coli Sequence Type 131 Strains from Nepal and Japan. MSphere, 2016, 1, .	3.1	8
196	Aminoglycoside Resistance. Infectious Disease Clinics of North America, 2016, 30, 523-537.	4.2	262
197	Fosfomycin: Resurgence of an old companion. Journal of Infection and Chemotherapy, 2016, 22, 273-280.	1.7	97
198	Carbapenem-Resistant Acinetobacter baumannii: Concomitant Contamination of Air and Environmental Surfaces. Infection Control and Hospital Epidemiology, 2016, 37, 777-781.	2.0	34

#	Article	IF	Citations
199	Initial-state splitting kernels in cold nuclear matter. Physics Letters, Section B: Nuclear, Elementary Particle and High-Energy Physics, 2016, 760, 706-712.	4.1	8
200	Reply to Iwata: Are all fosfomycins alike? Reply to author. Journal of Infection and Chemotherapy, 2016, 22, 725.	1.7	0
201	CD36 Provides Host Protection AgainstKlebsiella pneumoniaeIntrapulmonary Infection by Enhancing Lipopolysaccharide Responsiveness and Macrophage Phagocytosis. Journal of Infectious Diseases, 2016, 214, 1865-1875.	3.9	29
202	A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae. Mayo Clinic Proceedings, 2016, 91, 1362-1371.	2.8	95
203	Characterization of a Novel IncHI2 Plasmid Carrying Tandem Copies of bla _{CTX-M-2} in a fosA6 -Harboring Escherichia coli Sequence Type 410 Strain. Antimicrobial Agents and Chemotherapy, 2016, 60, 6742-6747.	3.4	12
204	Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections: Table 1.. Clinical Infectious Diseases, 2016, 63, 1615-1618.	5.7	373
205	Comparison of Minocycline Susceptibility Testing Methods for Carbapenem-Resistant Acinetobacter baumannii. Journal of Clinical Microbiology, 2016, 54, 2937-2941.	4.4	11
206	In Vitro Activity of Fusidic Acid-Containing Combinations against Carbapenem-Resistant Acinetobacter baumannii Clinical Strains. Antimicrobial Agents and Chemotherapy, 2016, 60, 5101-5101.	3.4	5
207	Comment on: Resistance gene naming and numbering: is it a new gene or not?. Journal of Antimicrobial Chemotherapy, 2016, 71, 2677-2678.	3.2	10
208	Glutathione-S-transferase FosA6 ofKlebsiella pneumoniaeorigin conferring fosfomycin resistance in ESBL-producingEscherichia coli. Journal of Antimicrobial Chemotherapy, 2016, 71, 2460-2465.	3.2	51
209	An â€œUnlikelyâ€•Pair: The Antimicrobial Synergy of Polymyxin B in Combination with the Cystic Fibrosis Transmembrane Conductance Regulator Drugs KALYDECO and ORKAMBI. ACS Infectious Diseases, 2016, 2, 478-488.	4.0	83
210	Differential effect of cholesterol on type I and II feline coronavirus infection. Archives of Virology, 2016, 161, 125-133.	1.9	15
211	Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infectious Diseases, The, 2016, 16, 161-168.	8.9	4,292
212	Carbapenems versus alternative antibiotics for the treatment of bloodstream infections caused byEnterobacter,CitrobacterorSerratiaspecies: a systematic review with meta-analysis. Journal of Antimicrobial Chemotherapy, 2016, 71, 296-306.	3.2	64
213	Complete Sequence of a Novel IncR-F33:Aâ€“:Bâ€“ Plasmid, pKP1034, Harboring fosA3 , bla _{KPC-2} , bla _{CTX-M-65} , bla _{SHV-12} , and rmtB from an Epidemic Klebsiella pneumoniae Sequence Type 11 Strain in China. Antimicrobial Agents and Chemotherapy, 2016, 60, 1343-1348.	3.4	52
214	Dissemination of the mcr-1 colistin resistance gene. Lancet Infectious Diseases, The, 2016, 16, 292-293.	8.9	153
215	Carbapenem-resistant and colistin-resistant Escherichia coli co-producing NDM-9 and MCR-1. Lancet Infectious Diseases, The, 2016, 16, 288-289.	8.9	218
216	Spectrum of excess mortality due to carbapenem-resistant Klebsiella pneumoniae infections. Clinical Microbiology and Infection, 2016, 22, 513-519.	6.5	97

#	Article	IF	Citations
217	Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. Journal of Antimicrobial Chemotherapy, 2016, 71, 1672-1680.	3.2	42
218	Emergence of the Plasmid-Mediated mcr-1 Gene in Colistin-Resistant Enterobacter aerogenes and Enterobacter cloacae. Antimicrobial Agents and Chemotherapy, 2016, 60, 3862-3863.	3.4	94
219	Anthelmintic closantel enhances bacterial killing of polymyxin B against multidrug-resistant Acinetobacter baumannii. Journal of Antibiotics, 2016, 69, 415-421.	2.1	30
220	Comparative analysis of an IncR plasmid carryingarmA,bla_{DHA-1}andqnrB4fromKlebsiella pneumoniaeST37 isolates. Journal of Antimicrobial Chemotherapy, 2016, 71, 882-886.	3.2	32
221	Complete Sequences of Multidrug Resistance Plasmids BearingrmtD1andrmtD216S rRNA Methyltransferase Genes. Antimicrobial Agents and Chemotherapy, 2016, 60, 1928-1931.	3.4	9
222	Coproduction of KPC-18 and VIM-1 Carbapenemases by Enterobacter cloacae: Implications for Newer Î²-Lactamâ€“Î²-Lactamase Inhibitor Combinations. Journal of Clinical Microbiology, 2016, 54, 791-794.	4.4	12
223	Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation. British Journal of Haematology, 2015, 169, 851-858.	2.7	66
224	Penicillins and Î²-Lactamase Inhibitors. , 2015, , 263-277.e3.		15
225	Genomic Epidemiology of an Endoscope-Associated Outbreak of Klebsiella pneumoniae Carbapenemase (KPC)-Producing K. pneumoniae. PLoS ONE, 2015, 10, e0144310.	2.5	75
226	Fosfomycin Resistance inEscherichia coli, Pennsylvania, USA. Emerging Infectious Diseases, 2015, 21, 2045-2047.	4.4	46
227	32: The Presence of an 11,111 m/z Peak in the Mass Spectrum of Escherichia coli Is Suggestive of Klebsiella pneumoniae Carbapenemase-Mediated Carbapenem Resistance. American Journal of Clinical Pathology, 2015, 143, A016-A016.	0.7	0
228	Carbapenemase-Producing Enterobacteriaceae. Seminars in Respiratory and Critical Care Medicine, 2015, 36, 074-084.	2.2	179
229	The Rise of Fluoroquinolone-ResistantEscherichia coliin the Community: Scarier Than We Thought. Journal of Infectious Diseases, 2015, 212, 1853-1855.	3.9	46
230	Pharmacokinetic interaction study of combining imatinib with dasatinib in rats by UPLCâ€“MS/MS. Drug Development and Industrial Pharmacy, 2015, 41, 1948-1953.	2.1	5
231	Complete Nucleotide Sequences of bla _{CTX-M} -Harboring IncF Plasmids from Community-Associated Escherichia coli Strains in the United States. Antimicrobial Agents and Chemotherapy, 2015, 59, 3002-3007.	3.4	39
232	Biodegradable dextran vesicles for effective haemoglobin encapsulation. Journal of Materials Chemistry B, 2015, 3, 5753-5759.	5.9	11
233	Complete Sequence of Conjugative IncA/C Plasmid Encoding CMY-2 Î²-Lactamase and RmtE 16S rRNA Methyltransferase. Antimicrobial Agents and Chemotherapy, 2015, 59, 4360-4361.	3.4	16
234	Acinetobacter baumannii: Evolution of Antimicrobial Resistanceâ€”Treatment Options. Seminars in Respiratory and Critical Care Medicine, 2015, 36, 085-098.	2.2	243

#	Article	IF	Citations
235	Screening for Methicillin-Resistant Staphylococcus aureus Colonization Using Sponges. Infection Control and Hospital Epidemiology, 2015, 36, 28-33.	2.0	7
236	In Vivo Evolution of CMY-2 to CMY-33 Î²-Lactamase in Escherichia coli Sequence Type 131: Characterization of an Acquired Extended-Spectrum AmpC Conferring Resistance to Cefepime. Antimicrobial Agents and Chemotherapy, 2015, 59, 7483-7488.	3.4	18
237	Commentary: Outbreak of Colistin-Resistant, Carbapenemase-Producing Klebsiella pneumoniae: Are We at the End of the Road?. Journal of Clinical Microbiology, 2015, 53, 3116-3117.	4.4	39
238	Clinical Appraisal of Fosfomycin in the Era of Antimicrobial Resistance. Antimicrobial Agents and Chemotherapy, 2015, 59, 7355-7361.	3.4	39
239	OXA-48-Producing Enterobacteriaceae Causing Bacteremia, United Arab Emirates. International Journal of Infectious Diseases, 2015, 30, 36-37.	3.3	16
240	Engineered Cationic Antimicrobial Peptides To Overcome Multidrug Resistance by ESKAPE Pathogens. Antimicrobial Agents and Chemotherapy, 2015, 59, 1329-1333.	3.4	110
241	Other Î²-Lactam Antibiotics. , 2015, , 293-297.e2.		9
242	Molecular Features of Community-Associated Extended-Spectrum-Î²-Lactamase-Producing Escherichia coli Strains in the United States. Antimicrobial Agents and Chemotherapy, 2014, 58, 6953-6957.	3.4	8
243	In Vitro Responses of Acinetobacter baumannii to Two- and Three-Drug Combinations following Exposure to Colistin and Doripenem. Antimicrobial Agents and Chemotherapy, 2014, 58, 1195-1199.	3.4	41
244	Safety and Efficacy of Long-Term Outpatient Ertapenem Therapy. Antimicrobial Agents and Chemotherapy, 2014, 58, 3437-3440.	3.4	21
245	Escherichia colisequence type 131: epidemiology and challenges in treatment. Expert Review of Anti-Infective Therapy, 2014, 12, 597-609.	4.5	16
246	Faropenem Disks for Screening of Klebsiella pneumoniae Carbapenemase-Producing Enterobacteriaceae: TABLE 1. Journal of Clinical Microbiology, 2014, 52, 3501-3502.	4.4	7
247	Escherichia coli Sequence Type 354 Coproducing CMY-2 Cephalosporinase and RmtE 16S rRNA Methyltransferase. Antimicrobial Agents and Chemotherapy, 2014, 58, 4246-4247.	3.4	13
248	Epidemiology and Clinical Outcomes of Patients with Carbapenem-Resistant Klebsiella pneumoniae Bacteriuria. Antimicrobial Agents and Chemotherapy, 2014, 58, 3100-3104.	3.4	32
249	Klebsiella pneumoniae Sequence Type 11 Isolate Producing RmtG 16S rRNA Methyltransferase from a Patient in Miami, Florida. Antimicrobial Agents and Chemotherapy, 2014, 58, 4980-4981.	3.4	10
250	CTX-M-15-D-ST648 Escherichia coli from companion animals and horses: another pandemic clone combining multiresistance and extraintestinal virulence?. Journal of Antimicrobial Chemotherapy, 2014, 69, 1224-1230.	3.2	162
251	Klebsiella pneumoniae ST147 Coproducing NDM-7 Carbapenemase and RmtF 16S rRNA Methyltransferase in Minnesota. Journal of Clinical Microbiology, 2014, 52, 4109-4110.	4.4	44
252	Complete Sequence of a Conjugative IncN Plasmid HarboringblaKPC-2,blaSHV-12, andqnrS1from an Escherichia coli Sequence Type 648 Strain. Antimicrobial Agents and Chemotherapy, 2014, 58, 6974-6977.	3.4	16

#	Article	IF	Citations
253	Whole-Genome Assembly of Klebsiella pneumoniae Coproducing NDM-1 and OXA-232 Carbapenemases Using Single-Molecule, Real-Time Sequencing. Antimicrobial Agents and Chemotherapy, 2014, 58, 5947-5953.	3.4	66
254	Microbiological features of KPC-producing Enterobacter isolates identified in a U.S. hospital system. Diagnostic Microbiology and Infectious Disease, 2014, 80, 154-158.	1.8	38
255	Treatment Options for Carbapenem-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Infections. Drugs, 2014, 74, 1315-1333.	11.1	181
256	Clinical Outcomes of Hospital-Acquired Infection with Acinetobacter nosocomialis and Acinetobacter pittii. Antimicrobial Agents and Chemotherapy, 2014, 58, 4172-4179.	3.4	123
257	Molecular Epidemiology of KPC-Producing Escherichia coli: Occurrence of ST131- fimH30 Subclone Harboring pKpQIL-Like IncFIIk Plasmid. Antimicrobial Agents and Chemotherapy, 2014, 58, 4234-4237.	3.4	36
258	Co-Production of NDM-1 and OXA-232 byKlebsiella pneumoniae. Emerging Infectious Diseases, 2014, 20, 163-165.	4.4	59
259	Prenatal development of the agouti (Dasyprocta prymnolopha Wagler, 1831): External features and growth curves. Animal Reproduction Science, 2013, 140, 195-205.	1.6	21
260	Mutations of the ompK36 Porin Gene and Promoter Impact Responses of Sequence Type 258, KPC-2-Producing Klebsiella pneumoniae Strains to Doripenem and Doripenem-Colistin. Antimicrobial Agents and Chemotherapy, 2013, 57, 5258-5265.	3.4	88
261	Risk factors for acquisition of multidrug-resistant Acinetobacter baumannii among cancer patients. American Journal of Infection Control, 2013, 41, 1249-1252.	2.5	44
262	Acinetobacter baumannii: Association between Environmental Contamination of Patient Rooms and Occupant Status. Infection Control and Hospital Epidemiology, 2013, 34, 517-520.	2.0	37
263	Community-Associated Extended-Spectrum Î²-Lactamaseâ€“Producing Escherichia coli Infection in the United States. Clinical Infectious Diseases, 2013, 56, 641-648.	5.7	281
264	Rational Design of Engineered Cationic Antimicrobial Peptides Consisting Exclusively of Arginine and Tryptophan, and Their Activity against Multidrug-Resistant Pathogens. Antimicrobial Agents and Chemotherapy, 2013, 57, 2511-2521.	3.4	152
265	Aerosolization of Acinetobacter baumannii in a Trauma ICU*. Critical Care Medicine, 2013, 41, 1915-1918.	0.9	53
266	Novel 16S rRNA Methyltransferase RmtH Produced by Klebsiella pneumoniae Associated with War-Related Trauma. Antimicrobial Agents and Chemotherapy, 2013, 57, 2413-2416.	3.4	51
267	Coproduction of 16S rRNA Methyltransferase RmtD or RmtG with KPC-2 and CTX-M Group Extended-Spectrum Î²-Lactamases in Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2013, 57, 2397-2400.	3.4	80
268	Activities of Vancomycin-Containing Regimens against Colistin-Resistant Acinetobacter baumannii Clinical Strains. Antimicrobial Agents and Chemotherapy, 2013, 57, 2103-2108.	3.4	65
269	Unique Structural Modifications Are Present in the Lipopolysaccharide from Colistin-Resistant Strains of Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy, 2013, 57, 4831-4840.	3.4	168
270	Epidemiology and Molecular Characterization of Bacteremia Due to Carbapenem-Resistant Klebsiella pneumoniae in Transplant Recipients. American Journal of Transplantation, 2013, 13, 2619-2633.	4.9	100

#	Article	IF	Citations
271	Characterization of the polarization mode dispersion of single mode fibre in KAT-7 telescope array network, South Africa. , 2013, , .		0
272	The CDKN2A and MAP Kinase Pathways. American Journal of Dermatopathology, 2013, 35, 167-175.	0.6	23
273	Quasiconvexity and relatively hyperbolic groups that split. Michigan Mathematical Journal, 2013, 62, .	0.4	24
274	Predatory Bacteria: A Potential Ally against Multidrug-Resistant Gram-Negative Pathogens. PLoS ONE, 2013, 8, e63397.	2.5	163
275	Features of Infections Due to Klebsiella pneumoniae Carbapenemaseâ€“Producing Escherichia coli: Emergence of Sequence Type 131. Clinical Infectious Diseases, 2012, 55, 224-231.	5.7	52
276	Clinical and Microbiologic Characteristics of Cephalosporin-Resistant Escherichia coli at Three Centers in the United States. Antimicrobial Agents and Chemotherapy, 2012, 56, 1870-1876.	3.4	31
277	Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly?. Journal of Antimicrobial Chemotherapy, 2012, 67, 1569-1577.	3.2	127
278	Dimensions of stable sets and scrambled sets in positive finite entropy systems. Ergodic Theory and Dynamical Systems, 2012, 32, 599-628.	0.7	15
279	Impact Metrics for Social Innovation: Barriers or Bridges to Radical Change?. Journal of Social Entrepreneurship, 2012, 3, 133-150.	2.4	83
280	Treatment Outcome of Bacteremia Due to KPC-Producing Klebsiella pneumoniae: Superiority of Combination Antimicrobial Regimens. Antimicrobial Agents and Chemotherapy, 2012, 56, 2108-2113.	3.4	472
281	Lack of Seasonality in the Occurrence of Multidrug-Resistant Acinectobacter baumannii Complex. Infection Control and Hospital Epidemiology, 2012, 33, 1051-1052.	2.0	17
282	Clinical characteristics of bacteraemia caused by extended-spectrum Î²-lactamase-producing Enterobacteriaceae in the era of CTX-M-type and KPC-type Î²-lactamases. Clinical Microbiology and Infection, 2012, 18, 887-893.	6.5	38
283	The role of horizontal gene transfer in the dissemination of extended-spectrum beta-lactamaseâ€“producing Escherichia coli and Klebsiella pneumoniae isolates in an endemic setting. Diagnostic Microbiology and Infectious Disease, 2012, 74, 34-38.	1.8	41
284	Occurrence of gravid Loa loa in subconjunctival space of man: a case report from West Bengal, India. Journal of Parasitic Diseases, 2012, 37, 52-5.	1.1	7
285	Escherichia coli Producing CMY-2 Î²-Lactamase in Retail Chicken, Pittsburgh, Pennsylvania, USA. Emerging Infectious Diseases, 2012, 18, 515-516.	4.4	10
286	Natural History of Multidrug-Resistant Acinetobacter baumannii Carriage in Intensive Care Units. Infection Control and Hospital Epidemiology, 2012, 33, 642-643.	2.0	4
287	Active and Passive Immunization Protects against Lethal, Extreme Drug Resistant-Acinetobacter baumannii Infection. PLoS ONE, 2012, 7, e29446.	2.5	150
288	Clinical evaluation of a new hearing aid anti-cardioid directivity pattern. International Journal of Audiology, 2011, 50, 249-254.	2.1	5

#	Article	IF	Citations
289	Risk factors and outcome of extended-spectrum Î²-lactamase-producing Enterobacter cloacae bloodstream infections. International Journal of Antimicrobial Agents, 2011, 37, 26-32.	3.3	68
290	Characterisation of clinical and food animal Escherichia coli isolates producing CTX-M-15 extended-spectrum Î²-lactamase belonging to ST410 phylogroup A. International Journal of Antimicrobial Agents, 2011, 37, 365-367.	3.3	44
291	High mortality rates among solid organ transplant recipients infected with extensively drug-resistant Acinetobacter baumannii: using in vitro antibiotic combination testing to identify the combination of a carbapenem and colistin as an effective treatment regimen. Diagnostic Microbiology and Infectious Disease, 2011, 70, 246-252.	1.8	68
292	Franchise Partnership and International Expansion: A Conceptual Framework and Research Propositions. Entrepreneurship Theory and Practice, 2011, 35, 533-557.	10.7	57
293	Economic value of Acinetobacter baumannii screening in the intensive care unit. Clinical Microbiology and Infection, 2011, 17, 1691-1697.	6.5	13
294	PME-1, an Extended-Spectrum Î²-Lactamase Identified in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2011, 55, 2710-2713.	3.4	24
295	Sequence Type ST405Escherichia coliIsolate Producing QepA1, CTX-M-15, and RmtB from Detroit, Michigan. Antimicrobial Agents and Chemotherapy, 2011, 55, 3966-3967.	3.4	18
296	Clinical Characteristics of Bloodstream Infections Due to Ampicillin-Sulbactam-Resistant, Non-Extended- Spectrum-Î²-Lactamase-Producing Escherichia coli and the Role of TEM-1 Hyperproduction. Antimicrobial Agents and Chemotherapy, 2011, 55, 495-501.	3.4	38
297	Identification of Diverse OXA-40 Group Carbapenemases, Including a Novel Variant, OXA-160, fromAcinetobacter baumanniiin Pennsylvania. Antimicrobial Agents and Chemotherapy, 2011, 55, 429-432.	3.4	39
298	Screening for Acinetobacter baumannii Colonization by Use of Sponges. Journal of Clinical Microbiology, 2011, 49, 154-158.	4.4	39
299	Molecular Epidemiology of Carbapenem-Nonsusceptible Acinetobacter baumannii in the United States. Journal of Clinical Microbiology, 2011, 49, 3849-3854.	4.4	122
300	Extended-Spectrum AmpC Cephalosporinase in Acinetobacter baumannii: ADC-56 Confers Resistance to Cefepime. Antimicrobial Agents and Chemotherapy, 2011, 55, 4922-4925.	3.4	69
301	Colistin-Resistant, Klebsiella pneumoniae Carbapenemase (KPC)-Producing Klebsiella pneumoniae Belonging to the International Epidemic Clone ST258. Clinical Infectious Diseases, 2011, 53, 373-376.	5.7	126
302	Extended-spectrum and CMY-type b-lactamase-producing Escherichia coli in clinical samples and retail meat from Pittsburgh, USA and Seville, Spain. Clinical Microbiology and Infection, 2010, 16, 33-38.	6.5	135
303	CTX-M as the predominant extended-spectrum Â-lactamases among Enterobacteriaceae in Manila, Philippines. Journal of Antimicrobial Chemotherapy, 2010, 65, 584-586.	3.2	18
304	Optimal Therapy for Multidrug-ResistantAcinetobacter baumannii. Emerging Infectious Diseases, 2010, 16, 171-171.	4.4	6
305	Clonal Distribution of Invasive Pneumococci, Czech Republic, 1996â€“2003. Emerging Infectious Diseases, 2010, 16, 287-289.	4.4	3
306	BordetellapertussisClones Identified by Multilocus Variable-Number Tandem-Repeat Analysis. Emerging Infectious Diseases, 2010, 16, 297-300.	4.4	33

#	Article	IF	Citations
307	Economic Impact of Acinetobacter baumannii Infection in the Intensive Care Unit. Infection Control and Hospital Epidemiology, 2010, 31, 1087-1089.	2.0	18
308	CTX-M-35 extended-spectrum Î²-lactamase conferring ceftazidime resistance in Citrobacter koseri. International Journal of Antimicrobial Agents, 2010, 35, 412-413.	3.3	4
309	Enhancing Resistance to Cephalosporins in Class C Î²-Lactamases: Impact of Gly214Glu in CMY-2. Biochemistry, 2010, 49, 1014-1023.	2.6	43
310	Klebsiella pneumoniae Carbapenemase-Producing Enterobacteriaceae, Northeast Florida. Southern Medical Journal, 2009, 102, 680-687.	0.7	3
311	Clinical Features and Molecular Epidemiology of CMYâ€Type Î²â€Lactamaseâ€“ProducingEscherichia coli. Clinical Infectious Diseases, 2009, 48, 739-744.	5.7	46
312	Reduced Susceptibility to Cefepime among Escherichia coli Clinical Isolates Producing Novel Variants of CMY-2 Î²-Lactamase. Antimicrobial Agents and Chemotherapy, 2009, 53, 3159-3161.	3.4	29
313	Molecular Epidemiology of CTX-M-Producing Escherichia coli Isolates at a Tertiary Medical Center in Western Pennsylvania. Antimicrobial Agents and Chemotherapy, 2009, 53, 4733-4739.	3.4	117
314	Extensively Drug-ResistantAcinetobacter baumannii. Emerging Infectious Diseases, 2009, 15, 980-982.	4.4	102
315	Activity of Temocillin against KPC-Producing Klebsiella pneumoniae and Escherichia coli. Antimicrobial Agents and Chemotherapy, 2009, 53, 2700-2701.	3.4	42
316	Interspecies Spread ofKlebsiella pneumoniaeCarbapenemase Gene in a Single Patient. Clinical Infectious Diseases, 2009, 49, 1736-1738.	5.7	95
317	Structure of AmpC Î²-lactamase (AmpCD) from anEscherichia coliclinical isolate with a tripeptide deletion (Gly286-Ser287-Asp288) in the H10 helix. Acta Crystallographica Section F: Structural Biology Communications, 2009, 65, 540-543.	0.7	6
318	CTX-M-2â€“ProducingSalmonellaTyphimurium Isolated from Pediatric Patients and Poultry in Brazil. Microbial Drug Resistance, 2009, 15, 317-321.	2.0	33
319	Fast Appraisal And Development Of A Stratigraphic Carbonate Play. , 2009, , .		2
320	Randomized Controlled Trial of Intravenous Dexamethasone to Prevent Relapse in Acute Migraine Headache. Headache, 2008, 48, 333-340.	3.6	54
321	Genetic Basis of Multidrug Resistance in Acinetobacter baumannii Clinical Isolates at a Tertiary Medical Center in Pennsylvania. Antimicrobial Agents and Chemotherapy, 2008, 52, 3837-3843.	3.4	145
322	Characterization of a Naturally Occurring Class D Î²-Lactamase from Achromobacter xylosoxidans. Antimicrobial Agents and Chemotherapy, 2008, 52, 1952-1956.	3.4	45
323	Reply to Falagas and Karageorgopoulos. Clinical Infectious Diseases, 2008, 46, 1122-1123.	5.7	2
324	Multiclonal Outbreak of Klebsiella pneumoniae Producing Extended-Spectrum Î²-Lactamase CTX-M-2 and Novel Variant CTX-M-59 in a Neonatal Intensive Care Unit in Brazil. Antimicrobial Agents and Chemotherapy, 2008, 52, 1790-1793.	3.4	60

#	Article	IF	Citations
325	Nomenclature of Plasmid-Mediated 16S rRNA Methylases Responsible for Panaminoglycoside Resistance. Antimicrobial Agents and Chemotherapy, 2008, 52, 2287-2288.	3.4	33
326	16S ribosomal RNA methylase RmtD produced by Klebsiella pneumoniae in Brazil. Journal of Antimicrobial Chemotherapy, 2008, 61, 746-747.	3.2	13
327	Escherichia coli Isolate Coproducing 16S rRNA Methylase and CTX-M-Type Extended-Spectrum Î²-Lactamase Isolated from an Outpatient in the United States. Antimicrobial Agents and Chemotherapy, 2008, 52, 1204-1205.	3.4	26
328	Genetic Environment of 16S rRNA Methylase Gene rmtD. Antimicrobial Agents and Chemotherapy, 2008, 52, 2270-2272.	3.4	15
329	High prevalence of CTX-M-15-producing Klebsiella pneumoniae among inpatients and outpatients with urinary tract infection in Southern India. Journal of Antimicrobial Chemotherapy, 2008, 61, 1393-1394.	3.2	69
330	High Prevalence of Metallo-Î²-Lactamase and 16S rRNA Methylase Coproduction among Imipenem-Resistant Pseudomonas aeruginosa Isolates in Brazil. Antimicrobial Agents and Chemotherapy, 2007, 51, 3388-3390.	3.4	48
331	Identification of 16S rRNA Methylase-Producing Acinetobacter baumannii Clinical Strains in North America. Antimicrobial Agents and Chemotherapy, 2007, 51, 4209-4210.	3.4	64
332	A Step Closer to Extreme Drug Resistance (XDR) in Gram-Negative Bacilli. Clinical Infectious Diseases, 2007, 45, 1179-1181.	5.7	123
333	Detection of plasmid-mediated class C Î²-lactamases. International Journal of Infectious Diseases, 2007, 11, 191-197.	3.3	71
334	16S Ribosomal RNA Methylation: Emerging Resistance Mechanism against Aminoglycosides. Clinical Infectious Diseases, 2007, 45, 88-94.	5.7	597
335	Coproduction of Novel 16S rRNA Methylase RmtD and Metallo-Î²-Lactamase SPM-1 in a Panresistant Pseudomonas aeruginosa Isolate from Brazil. Antimicrobial Agents and Chemotherapy, 2007, 51, 852-856.	3.4	99
336	Community-acquired Extended-Spectrum Î²-Lactamase Producers, United States. Emerging Infectious Diseases, 2007, 13, 1121-1123.	4.4	40
337	KPC Type B-Lactamase, Rural Pennsylvania. Emerging Infectious Diseases, 2006, 12, 1613-1614.	4.4	20
338	PCR Classification of CTX-M-Type Î²-Lactamase Genes Identified in Clinically Isolated Gram-Negative Bacilli in Japan. Antimicrobial Agents and Chemotherapy, 2006, 50, 791-795.	3.4	133
339	Outer Membrane Protein Changes and Efflux Pump Expression Together May Confer Resistance to Ertapenem in Enterobacter cloacae. Antimicrobial Agents and Chemotherapy, 2006, 50, 2833-2835.	3.4	83
340	Novel Plasmid-Mediated 16S rRNA Methylase, RmtC, Found in a Proteus mirabilis Isolate Demonstrating Extraordinary High-Level Resistance against Various Aminoglycosides. Antimicrobial Agents and Chemotherapy, 2006, 50, 178-184.	3.4	107
341	Global Spread of Multiple Aminoglycoside Resistance Genes. Emerging Infectious Diseases, 2005, 11, 951-953.	4.4	126
342	Practical Methods Using Boronic Acid Compounds for Identification of Class C Î²-Lactamase-Producing Klebsiella pneumoniae and Escherichia coli. Journal of Clinical Microbiology, 2005, 43, 2551-2558.	4.4	145

#	Article	IF	Citations
343	Escherichia coliProducing CTX-M-2 Î²-Lactamase in Cattle, Japan. Emerging Infectious Diseases, 2004, 10, 69-75.	4.4	97
344	Spread of Novel Aminoglycoside Resistance Gene aac (6 â€²)- Iad among Acinetobacter Clinical Isolates in Japan. Antimicrobial Agents and Chemotherapy, 2004, 48, 2075-2080.	3.4	44
345	Plasmid-Mediated 16S rRNA Methylase in Serratia marcescens Conferring High-Level Resistance to Aminoglycosides. Antimicrobial Agents and Chemotherapy, 2004, 48, 491-496.	3.4	168
346	Nosocomial Spread of Ceftazidime-Resistant Klebsiella pneumoniae Strains Producing a Novel Class A Î²-Lactamase, GES-3, in a Neonatal Intensive Care Unit in Japan. Antimicrobial Agents and Chemotherapy, 2004, 48, 1960-1967.	3.4	64
347	Inhibitor-Sensitive AmpC Î²-Lactamase Variant Produced by an Escherichia coli Clinical Isolate Resistant to Oxyiminocephalosporins and Cephamycins. Antimicrobial Agents and Chemotherapy, 2004, 48, 2652-2658.	3.4	43
348	Genetic Environments of the rmtA Gene in Pseudomonas aeruginosa Clinical Isolates. Antimicrobial Agents and Chemotherapy, 2004, 48, 2069-2074.	3.4	57
349	Molecular Characterization of a Cephamycin-Hydrolyzing and Inhibitor-Resistant Class A Î²-Lactamase, GES-4, Possessing a Single G170S Substitution in the Î©-Loop. Antimicrobial Agents and Chemotherapy, 2004, 48, 2905-2910.	3.4	64
350	PCR Typing of Genetic Determinants for Metallo-Â-Lactamases and Integrases Carried by Gram-Negative Bacteria Isolated in Japan, with Focus on the Class 3 Integron. Journal of Clinical Microbiology, 2003, 41, 5407-5413.	4.4	301
351	A novel apoptosis-inducing protein from Helicobacter pylori. Molecular Microbiology, 2003, 47, 443-451.	2.5	97
352	Acquisition of 16S rRNA methylase gene in Pseudomonas aeruginosa. Lancet, The, 2003, 362, 1888-1893.	12.1	200
353	A New TEM-Derived Extended-Spectrum Î²-Lactamase (TEM-91) with an R164C Substitution at the Î©-Loop Confers Ceftazidime Resistance. Antimicrobial Agents and Chemotherapy, 2003, 47, 2981-2983.	3.4	11
354	Characterization of a Novel Plasmid-Mediated Cephalosporinase (CMY-9) and Its Genetic Environment in an Escherichia coli Clinical Isolate. Antimicrobial Agents and Chemotherapy, 2002, 46, 2427-2434.	3.4	54
355	IMP-1 type Metalo-^|^beta;-lactamase Producing Serratia marcescens Strains Isolated from Blood Culture between 1991 to 2000. Journal of the Japanese Association for Infectious Diseases, 2002, 76, 246-253.	0.0	3
356	CHARACTERIZATION OF KLEBSIELLA PNEUMONIAE AND ESCHERICHIA COLI STRAINS THAT PRODUCE CTX-M-2-TYPE BROAD SPECTRUM BETA-LACTAMASE ISOLATED FROM A CHILD WITH LEUKEMIA. Pediatric Infectious Disease Journal, 2002, 21, 260-262.	2.0	6
357	Synthesis of variously oxidized abietane diterpenes and their antibacterial activities against MRSA and VRE. Bioorganic and Medicinal Chemistry, 2001, 9, 347-356.	3.1	86
358	Apoptotic Signaling Pathway Activated by Helicobacter pylori Infection and Increase of Apoptosis-Inducing Activity under Serum-Starved Conditions. Infection and Immunity, 2001, 69, 3181-3189.	2.4	55
359	Chromosomal 16S Ribosomal RNA Methyltransferase RmtE1 in Escherichia coli Sequence Type 448. Emerging Infectious Diseases, 2000, 23, 876-878.	4.4	7
360	Expression of Î±-calcitonin gene-related peptide in the enteric nervous system of rat small intestine. Neuroscience Letters, 2000, 285, 33-36.	2.1	10

#	Article	IF	Citations
361	Normal Development of Mice and Unimpaired Cell Adhesion/Cell Motility/Actin-based Cytoskeleton without Compensatory Up-regulation of Ezrin or Radixin in Moesin Gene Knockout. Journal of Biological Chemistry, 1999, 274, 2315-2321.	3.5	150
362	Moesin Is Not a Receptor for Measles Virus Entry into Mouse Embryonic Stem Cells. Journal of Virology, 1998, 72, 1586-1592.	3.5	15
363	Polymorphism of the angiotensin-converting enzyme (ACE) gene in patients with thrombotic brain infarction. Atherosclerosis, 1997, 132, 145-150.	0.8	55
364	Increase in number of Weibel-Palade bodies and endothelin-1 release from endothelial cells in the cadmium-treated rat thoracic aorta. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 1996, 428, 367-73.	2.9	19
365	Histamine release from Weibel-Palade bodies of toad aortas induced by endothelin-1 and sarafotoxin-S6b. The Anatomical Record, 1995, 242, 374-382.	1.6	17
366	Vasocontractions of the in-vitro toad aortas induced by endothelin-1 and sarafotoxin-S6b. The Anatomical Record, 1993, 235, 253-260.	1.6	7
367	A possible model: Photothermal excitation via an excited state in the Si:Pd level. Journal of Applied Physics, 1988, 64, 5266-5269.	2.3	2
368	Reed-Sternberg cells in Hodgkin's cell lines HDLM, L-428, and KM-H2 are not actively replicating: lack of bromodeoxyuridine uptake by multinuclear cells in culture. Blood, 1988, 71, 1382-1389.	1.4	35
369	Congenital malformation of the feet with low body height. Clinical Genetics, 1977, 12, 255-262.	2.2	17
370	Carotenoid Pigments in Tubers of the Katahdin Variety of Irish Potato. Plant Physiology, 1947, 22, 421-437.	5.1	17
371	Von Bï¿½chern allgemein analytischen Inhaltes. Analytical and Bioanalytical Chemistry, 1903, 42, 519-522.	3.9	0
372	Global Spread of Multidrug-Resistant Gram-Negative Bacilli. , 0, , 213-222.		0
373	Title is missing!. , 0, , .		0
374	Comparison of three rapid diagnostic tests for bloodstream infections using Benefit-risk Evaluation Framework (BED-FRAME). Journal of Clinical Microbiology, 0, , .	4.4	0
375	In Vivo Evolution of a Klebsiella pneumoniae Capsule Defect With wcaJ Mutation Promotes Complement-Mediated Opsonophagocytosis During Recurrent Infection. Journal of Infectious Diseases, 0, , .	3.9	0
376	The relationship between self-stigma and quality of life in long-term hospitalized patients with schizophrenia: a cross-sectional study. Frontiers in Psychiatry, 0, 15, .	2.7	0
377	Clinical characteristics and genome epidemiology of Stenotrophomonas maltophilia in Japan. Journal of Antimicrobial Chemotherapy, 0, , .	3.2	0
378	Clinical outcomes in patients infected with ertapenem-only-resistant Enterobacterales versus multi-carbapenem-resistant Enterobacterales. Journal of Antimicrobial Chemotherapy, 0, , .	3.2	0

#	Article	IF	Citations
379	Paediatric very rare tumours registration and management in European countries with low health expenditure average rates. Clinical and Translational Oncology, 0, , .	2.5	0
380	Increased mortality in hospital- compared to community-onset carbapenem-resistant enterobacterales infections. Journal of Antimicrobial Chemotherapy, 0, , .	3.2	0
381	Characterization of Pseudomonas aeruginosa from subjects with diffuse panbronchiolitis. Microbiology Spectrum, 0, , .	3.0	0